Effect of mesenchymal stem cells‐derived exosomes on tumor microenvironment: Tumor progression versus tumor suppression
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are multipotent cells with the potential to differentiate into different cell types. Owing to their immunosuppressive and anti‐inflammatory properties, they are widely used in regenerative medicine, but they have a dual effect on cancer progression and exert both growth‐stimulatory or ‐inhibitory effects on different cancer types. It has been proposed that these controversial effects of MSC in tumor microenvironment (TME) are mediated by their polarization to proinflammatory or anti‐inflammatory phenotype. In addition, they can polarize the immune system cells that in turn influence tumor progression. One of the mechanisms involved in the TME communications is extracellular vesicles (EVs). MSCs, as one of cell populations in TME, produce a large amount of EVs that can influence tumor development. Similar to MSC, MSC‐EVs can exert both anti‐ or protumorigenic effects. In the current study, we will investigate the current knowledge related to MSC role in cancer progression with a focus on the MSC‐EV content in limiting tumor growth, angiogenesis, and metastasis. We suppose MSC‐EVs can be used as safe vehicles for delivering antitumor agents to TME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151 · cited 2×
“In addition, hUC‐MSC reduced the expression of X‐linked inhibitor of apoptosis protein (XIAP), which resulted in dysregulation of PI3K/Akt signaling pathway and inhibition of glioma cell survival (Dasari et al., 2010).”
BackgroundRetractedMatrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 3×
“CCL5 increased extravasation of cancer cell and promoted tumor cell metastasis (Karnoub et al., 2007).”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992 · cited 1×
“It seems that therapeutic effects of MSC is not related to their differentiation potential into various cell types and is related to paracrine or juxtacrine factors produced by them (Caplan & Dennis, 2006).”
BackgroundRegulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260 · cited 1×
“Then after, MVBs can follow secretory or degradative pathway (Robbins & Morelli, 2014).”
BackgroundA cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“Innate immunity compartments, including natural killer cells (NKCs), dendritic cells (DCs), and macrophages are able to detect and remove tumor cells but immunosuppressive environment of tumor impaired their function and allowed immune system evasion of tumor cells (W. W. Lin & Karin, 2007).”
BackgroundBiogenesis and secretion of exosomes
Kowal, J., Tkach, M., & Théry, C. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.05.004 · Cited by 1,781
Ectosomes and exosomes: shedding the confusion between extracellular vesicles
Cocucci, E., & Meldolesi, J. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.01.004 · Cited by 1,435 · cited 1×
“MVBs are endocytic structures that are generated by inward budding of endosomal membrane and releasing of ILVs into them (Cocucci & Meldolesi, 2015).”
BackgroundVesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
Kalra, H., Simpson, R. J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V. C., Borràs, F. E., Breakefield, X., Budnik, V., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001450 · Cited by 1,367 · cited 1×
“Exocarta, Vesiclepedia, and EVpedia are examples of these databases (Kalra et al., 2012; D. K. Kim et al., 2013; Mathivanan & Simpson, 2009).”
BackgroundExosomes: secreted vesicles and intercellular communications
Théry, C. (2011) · F1000 Biology Reports · doi:10.3410/b3-15 · Cited by 989
Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives
Liang, X., Ding, Y., Zhang, Y., Tse, H.-F., & Lian, Q. (2014) · Cell Transplantation · doi:10.3727/096368913x667709 · Cited by 909
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614 · cited 1×
“Cell proliferation, migration, differentiation, and apoptosis are biological processes that are regulated by miRNAs, and dysregulation of miRNAs expression can lead to pathological conditions, such as cancer (Godlewski et al., 2008; Y. Li et al., 2009).”
BackgroundKlopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 3×
“injection, they may promote or inhibit tumor (Klopp et al., 2011).”
BackgroundAdipose tissue-derived mesenchymal stem cells as a source of human hepatocytes
Banas, A., Teratani, T., Yamamoto, Y., Tokuhara, M., Takeshita, F., Quinn, G., Okochi, H., & Ochiya, T. (2007) · Hepatology · doi:10.1002/hep.21704 · Cited by 555
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo
Zhu, W., Huang, L., Li, Y., Zhang, X., Gu, J., Yan, Y., Xu, X., Wang, M., Qian, H., & Xu, W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.10.002 · Cited by 488
Turturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388 · cited 2×
“The interaction between DAMP molecules on the dying cells’ surface and DC receptors activate DCs and induce native immune responses against the tumor (Spisek et al., 2007).”
BackgroundMesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386
Mesenchymal stem cells enhance growth and metastasis of colon cancer
Shinagawa, K., Kitadai, Y., Tanaka, M., Sumida, T., Kodama, M., Higashi, Y., Tanaka, S., Yasui, W., & Chayama, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25440 · Cited by 308
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305 · cited 1×
“MSCs’ effect on cancer cells are variable and depend on cancer type, stage, microenvironment, mutations, and acquired resistance status of the cancer cell lines (Klopp et al., 2011; Roodhart et al., 2011).”
BackgroundHung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0876 · Cited by 268 · cited 1×
“MSCs tumor homing have been observed in some cancers, such as breast, ovarian, lung, and colon carcinomas (Goldstein, Reagan, Anderson, Kaplan, & Rosenblatt, 2010; Hung et al., 2005; Komarova, Roth, Alvarez, Curiel, & Pereboeva, 2010).”
Xu, J.-F., Yang, G.-H., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114627 · Cited by 235 · cited 1×
“It has been reported that MSC‐EV miRNAs are involved in apoptosis prevention, cardiac fibrosis reduction, and tumor growth inhibition (Xu et al., 2014).”
BackgroundTherapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model
Sun, B., Roh, K.-H., Park, J.-R., Lee, S.-R., Park, S.-B., Jung, J.-W., Kang, S.-K., Lee, Y.-S., & Kang, K.-S. (2009) · Cytotherapy · doi:10.1080/14653240902807026 · Cited by 214 · cited 1×
“Coinjection of MSCs with tumor cells has similar results (B. Sun et al., 2009).”
ResultMechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
Compte, M., Cuesta, Á. M., Sánchez-Martín, D., Alonso-Camino, V., Vicario, J. L., Sanz, L., & Álvarez-Vallina, L. (2009) · Stem Cells · doi:10.1634/stemcells.2008-0831 · Cited by 96 · cited 2×
“, 2004), and second, subcutaneously transplantation of MSC‐loaded artificial scaffold matrix close to the tumor (Compte et al., 2009).”
BackgroundTu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95 · cited 1×
“Some evidence show that MSCs promote tumor angiogenesis, metastasis, and drug resistance that lead to tumor progression (Hill, Pelagalli, Passaro, & Zannetti, 2017; Karnoub et al., 2007; Tu et al., 2016; T. Zhang et al., 2013).”
BackgroundFontanella, R., Pelagalli, A., Nardelli, A., D'Alterio, C., Ieranò, C., Cerchia, L., Lucarelli, E., Scala, S., & Zannetti, A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.018 · Cited by 79 · cited 2×
“this study, a new CXCR4 inhibitor, peptide R, was used to hamper BM‐MSCs and tumor cells interactions (Fontanella et al., 2016).”
MethodJia, X.-H., Feng, G.-W., Wang, Z.-L., Du, Y., Shen, C., Hui, H., Peng, D., Li, Z.-J., Kong, D.-L., & Tian, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8064 · Cited by 62 · cited 2×
“MSCs can influence macrophage polarization and function (Jia et al., 2016).”
BackgroundInfluence of mesenchymal stem cells on metastasis development in mice in vivo
Meleshina, A. V., Cherkasova, E. I., Shirmanova, M. V., Klementieva, N. V., Kiseleva, E. V., Snopova, L. В., Prodanets, N. N., & Zagaynova, E. V. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0003-7 · Cited by 45
Cited by
Casado-Díaz, A., Quesada-Gómez, J. M., & Dorado, G. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00146 · Cited by 313
Afkhami, H., Mahmoudvand, G., Fakouri, A., Shadab, A., Mahjoor, M., & Komeili Movahhed, T. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1255697 · Cited by 27
Sousa, A., Coelho, P., Leite, F., Teixeira, C., Rocha, A. C., Santos, I., Baylina, P., Fernandes, R., Soares, R., Costa, R., et al. (2023) · Human Cell · doi:10.1007/s13577-023-00880-z · Cited by 15
“These acellular therapies are therefore based on the principle, already demonstrated, that the therapeutic effects associated with UC-MSC are mainly due to paracrine factors [14].”
BackgroundDidamoony, M. A., Soubh, A. A., & Ahmed, L. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01784-7 · Cited by 9
“In addition, Shojaei et al. [114] used electroporation to package miR-381-3p mimic into MSC-EXOs and deliver it to triple-negative breast cancer cells to inhibit their migration.”
Metadata
- Authors
- Shojaei, S., Hashemi, S. M., Ghanbarian, H., Salehi, M., & Mohammadi‐Yeganeh, S.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-10-26
- Volume
- 234
- Issue
- 4
- Pages
- 3394-3409
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2898177310
- Cited by
- 84
- References
- 33
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.